Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Partners With Turbine to Identify Treatment Resistance in Blood Cancers

NEW YORK – Turbine, a biological simulation company, on Friday announced a collaboration with AstraZeneca to better understand the mechanisms of resistance to treatment of hematological cancers.

The collaboration will focus on resistance mechanisms resulting from altered protein-protein interactions, which could help guide treatment based on a patient's molecular profile. Turbine will use its cell simulation platform to map how signaling proteins interact to characterize cancer cell behavior and response to treatment. Financial details of the collaboration were not disclosed.

London-based Turbine previously worked with AstraZeneca to predict combination approaches and identify biomarker candidates within DNA damage repair mechanisms.

"Over the past several years, Turbine has been working with researchers at AstraZeneca to evaluate our platform's ability to identify mechanisms and potential biomarkers of response or resistance to personalized treatment combinations," Turbine CEO Szabolcs Nagy said in a statement. "The collaboration announced today builds on the promise our platform has shown and will see us apply this technology to answer new questions about molecular alterations that give rise to drug resistance and how they could be overcome."